Sanofi (EPA:SAN) has been assigned a €85.00 ($100.00) price objective by analysts at Barclays in a research note issued to investors on Tuesday, Borsen Zeitung reports. The brokerage presently has a “neutral” rating on the stock. Barclays‘s price objective indicates a potential upside of 1.05% from the company’s previous close.
A number of other brokerages have also weighed in on SAN. Credit Suisse Group set a €96.00 ($112.94) price objective on Sanofi and gave the company a “buy” rating in a report on Tuesday. JPMorgan Chase & Co. set a €93.00 ($109.41) price objective on Sanofi and gave the company a “buy” rating in a report on Monday, March 15th. The Goldman Sachs Group set a €106.00 ($124.71) price objective on Sanofi and gave the company a “buy” rating in a report on Monday, March 15th. UBS Group set a €101.00 ($118.82) price target on shares of Sanofi and gave the company a “buy” rating in a research report on Wednesday, February 10th. Finally, Deutsche Bank Aktiengesellschaft set a €70.00 ($82.35) price target on shares of Sanofi and gave the company a “sell” rating in a research report on Thursday, April 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of €97.75 ($115.00).
Shares of SAN opened at €84.12 ($98.96) on Tuesday. Sanofi has a twelve month low of €63.09 ($74.22) and a twelve month high of €92.97 ($109.38). The stock’s 50 day moving average is €80.26 and its two-hundred day moving average is €81.70.
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
Further Reading: Debt-To-Equity Ratio
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.